Blinatumomab
About
Therapy type: Immunotherapy
Therapy strategy: CD19 inhibition
Mappings
NCI Thesaurus: Blinatumomab (ncit:C62528)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Blinatumomab |